A multicenter cohort study of Tovastan combined with Shenfu Xiaozheng Decoction in the treatment of ADPKD patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005823

Enrollment

Unknown

Registered

2022-04-07

Start date

2022-04-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADPKD

Interventions

3:Tolvaptan+traditional Chinese medicine

1:Basic Western medicine treatment

4:traditional Chinese medicine

2:Tolvaptan

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Patients with ADPKD diagnosed according to renal imaging according to the diagnostic criteria of ADPKD in The Division of Nephrology of Internal Medicine; ? Complete clinical and pathological data; ? Age 18-70; ? GFR=30ml/(min Q. 73m2)(CKD1 ~ 3 stage).

Exclusion criteria

Exclusion criteria: ? Complicated with other glomerular diseases; ? Patients with serious diseases such as heart, brain, lung and blood system; ? Pregnant or lactating women; ? Incomplete medical data. ? According to the judgment of the researcher, it is not suitable for the candidate.

Design outcomes

Primary

Measure	Time frame
eGFR;total kidney volume, TKV;serum creatinine;	—

Countries

China

Contacts

Public ContactHong yu Chen

616680813@qq.com15700067201

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026